Nicotine patch safe during pregnancy
This article was originally published in The Tan Sheet
Long-term nicotine replacement therapy advocated for pregnant women otherwise unable to stop smoking by Paul Ogburn, MD, State University of New York at Stony Brook, et al. Researchers found 22 mg/24 hrs of transdermal nicotine therapy administered for eight weeks did not affect gestational age, birth weight or "fetal well-being" in cohort of 21 pregnant smokers. Study was presented at Society for Maternal-Fetal Medicine's annual meeting in New Orleans Jan. 17 and published in December American Journal of Obstetrics & Gynecology. A California judge ruled last March against requiring that nonprescription NRT products carry labeling stating they "can harm your baby" (1"The Tan Sheet" March 26, 2001, p. 21)...
You may also be interested in...
Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Viatris has weighed in on the FTC’s continued investigations into US healthcare middlemen, arguing that it can be a good thing for an industry battling shortages, even as the firm continues to rationalize products that do not make sense economically.